CJC-1295 + Ipamorelin (5mg/5mg) · Research brief
CJC-1295 Research Strength Considerations for Buyers
Short answer
CJC-1295 Research Strength Considerations For a wholesale buyer, the "strength" of a CJC-1295 vial is not one number — it is three. There is the labeled peptide mass, the net peptide content once counterions and residual water are subtracted from that mass, and the chromatographic purity of whatever peptide is present.
CJC-1295 Research Strength Considerations
For a wholesale buyer, the "strength" of a CJC-1295 vial is not one number — it is three. There is the labeled peptide mass, the net peptide content once counterions and residual water are subtracted from that mass, and the chromatographic purity of whatever peptide is present. A label that reads 10mg describes intent; a lot-matched certificate of analysis describes result. Everything below is about closing the distance between those two things before you commit to a purchase order, and all compounds discussed here are supplied for laboratory research use only.
Strength is three numbers, not one
Start with gross mass. A lyophilized research peptide is weighed and filled as a dry cake, and that fill weight is what most labels report. It is a real number, but it describes everything in the vial, not just the peptide chain.
Synthetic peptides produced by solid-phase synthesis are typically purified by reverse-phase chromatography and isolated as salts. That means a portion of the dry mass is counterion — commonly trifluoroacetate or acetate depending on the purification and any salt-exchange step. Lyophilized material also retains residual water, and the amount varies with the drying cycle. Net peptide content is the figure that accounts for these: the percentage of the dry mass that is actually peptide. It is determined by methods such as amino acid analysis or nitrogen determination, not by weighing the vial.
The third number is purity, and it answers a different question entirely: of the peptide that is present, how much of it is the target sequence rather than deletion sequences, truncations, oxidation products, or dimers. High-performance liquid chromatography reports this as the area percentage of the main peak. A batch can be high-purity and still have modest net peptide content, or the reverse. The two figures do not substitute for one another, and a supplier who reports only one is giving you half of the picture.
For research planning, this matters because reproducibility depends on knowing the molar quantity you are working with. A laboratory that treats gross fill weight as peptide mass is building a systematic error into every calculation downstream, and that error will not be constant across suppliers or across batches.
Why DAC and no-DAC vials are not interchangeable by milligram
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on a modified fragment of the native GHRH sequence with substitutions intended to resist enzymatic degradation. Two distinct materials circulate under closely related names, and confusing them is the most common ordering error in this category.
The DAC version incorporates a drug affinity complex — a maleimide group designed to conjugate with serum albumin. Published research indicates this conjugation substantially extends the circulating half-life of the analogue in study models compared with the unconjugated form. The no-DAC version, frequently catalogued as modified GRF (1-29), omits that group entirely and behaves very differently in pharmacokinetic research.
The practical consequence for a buyer is that the two molecules have different molecular weights. Equal milligram masses are therefore not equal molar amounts, and a study design that swaps one for the other on a milligram basis has changed two variables at once. Because the naming conventions in this category are inconsistent across the industry, the only reliable identity check is the sequence and molecular weight printed on the certificate of analysis, confirmed by a mass spectrometry result. If a listing says "CJC-1295" without specifying DAC status, treat that as an unanswered question rather than a formatting shortcut.
Research interest in this class generally sits alongside work on growth hormone secretagogues that act through a separate receptor pathway, which is why comparative and combination studies are common in the literature. That is a compound-science observation, not a recommendation about use.
How a vial's contents are actually established
Analytical verification is a sequence, and each step answers one question. Mass spectrometry establishes identity: does the observed molecular weight match the expected sequence. HPLC establishes purity: what fraction of the chromatogram is the main peak. Net peptide content establishes quantity. Contaminant panels establish what else came along — endotoxin and bioburden screening, heavy metals, residual solvents from synthesis and cleavage, and water content from the lyophilization cycle.
None of these is optional if reproducibility matters, and none of them is inferable from packaging. A vial can look immaculate and still carry an unacceptable endotoxin result, because endotoxin is not visible. Conversely, a cake that has collapsed or looks sparse is not necessarily out of specification — fill volume and cake appearance vary with the drying protocol.
The question that separates real documentation from decoration is whether the report is tied to your lot. Many suppliers publish a single representative document per product and leave it there for years. That tells you a batch was tested once. It does not tell you the vial in your hand came from that batch, and for a buyer reordering quarterly, it is the reorders where variance shows up.
Ask also who performed the testing. In-house quality control is legitimate and normal, but independent third-party analysis carries different evidentiary weight, and a supplier should be able to say plainly which one produced each figure on the document.
What each document actually proves
| Document | What it establishes | What it does not establish |
|---|---|---|
| Product-level COA posted on a site | A batch of this product was tested at some point | That your vial came from that batch |
| Lot-matched COA | The tested material carries the lot number on your vial | Anything about handling after dispatch |
| HPLC chromatogram | Chromatographic purity of the main peak | The identity of the molecule |
| Mass spectrometry result | Molecular identity and DAC status | Quantity or purity |
| Net peptide content figure | How much of the dry mass is peptide | The purity of that peptide |
| Endotoxin and bioburden results | Contaminant screening on that batch | Stability across the shelf life |
Read the table as a checklist for gaps. If a supplier can produce four of these six for the lot you received, you know precisely which two questions remain open, and you can decide whether that is acceptable for your catalog.
Questions to put to a supplier before the first order
Before a first wholesale order, the useful questions are procedural rather than promotional. Can the supplier produce a lot-matched COA for the specific batch being shipped, without an additional fee and without a support ticket? Is the certificate published where a buyer — or a buyer's own customer — can retrieve it independently? Does the document report both purity and net peptide content, or only the flattering one? Is the analysis in-house, third-party, or a mix, and is that labeled?
Then move to consistency. Batch-to-batch variance is the quiet problem in this industry, because the first order is usually fine. What a reseller needs is the second, fifth, and twelfth order to match. Ask how long certificates are retained and whether historical lots stay accessible after they sell through, because that archive is what lets you demonstrate consistency to a customer months later. Ask about storage and shipping conditions for lyophilized material, and about how the supplier handles a batch that falls out of specification — quarantine and re-test, or quiet release.
Finally, look at how pricing is presented. Programs that require a call before quoting a number, or that charge separately for analytical documentation, are making a choice about transparency that tells you something. Contrast that with published tiering and freely available certificates, and the comparison is easy to make without anyone naming names. Margins and minimums vary widely by category and volume across this market, so evaluate any program against the documentation it will actually hand you rather than against a headline figure.
Compliance questions that belong with your counsel
This section is informational and is not legal advice. Whether a given business may purchase, hold, relabel, or resell research compounds depends on your entity type, your professional licensure, your state's rules, and the terms of any license you hold. Those are questions for your attorney and your state board, not for a supplier's blog post, and the answers differ enough that no general statement here would be safe to rely on.
The useful posture is to arrive at that conversation with the right questions: what my license does and does not permit me to stock; what recordkeeping I am expected to maintain for research-use-only materials; what labeling obligations attach to anything I resell; and what my advertising may and may not say. If any part of your inquiry touches a clinical or veterinary context, that belongs with a licensed physician or a veterinarian and with your counsel — this article addresses catalog and procurement decisions only, and the compounds discussed are not approved drugs and are not for human consumption.
What Real Peptides does differently
Real Peptides tests to 99%+ HPLC purity and runs a 7-panel batch testing program, and the resulting certificates of analysis are published for buyers to verify themselves rather than supplied on request or sold as an add-on. That last point is the operational difference: a partner can point a customer at the documentation directly instead of acting as an intermediary for it.
Fulfillment is handled from within the United States, with orders shipping in 5–7 days, which matters for resellers who carry limited shelf inventory and reorder on a short cycle. Access runs through a three-step Wholesale Partner Program application — submit business details, complete review and approval, then order against partner pricing. Pricing structure is disclosed to approved partners rather than negotiated case by case, which removes the guesswork from building a catalog around it.
None of that is a claim about what any compound does or about what any business will earn. It is a description of the documentation and logistics a wholesale buyer receives, which is the part a supplier can actually be held to.
If you operate a med spa, clinic, telehealth business, or reseller brand and the verification standards above match how you want to source, the Wholesale Partner Program application is the next step — it takes business details, a short review, and approval before partner pricing opens.
For readers comparing specific materials, Real Peptides lists CJC-1295 No DAC 10mg alongside related secretagogue research compounds including Ipamorelin 10mg and Tesamorelin 10mg, with broader catalog context available through the Growth Factor & Tissue Signaling Research and Performance & Recovery Research collections, and the wider Popular Peptides range for buyers building a first wholesale order.
Build a pack
Researching more than one compound?
Build a multi-vial pack and the discount applies automatically as you add doses.
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA